1. Downregulation of lncRNA-SRA participates in the development of cardiovascular disease in type II diabetic patients.
- Author
-
Ren, Shuang, Zhang, Yi, Li, Bixun, Bu, Kunpeng, Wu, Lili, Lu, Yang, Lu, Yanyan, and Qiu, Ye
- Subjects
CARDIOVASCULAR development ,CARDIOVASCULAR diseases ,VASCULAR smooth muscle ,STEROID receptors ,NON-coding RNA - Abstract
Long non-coding RNA steroid receptor RNA activator (lncRNA-SRA) has been proven to regulate vascular smooth muscle cell (VSMC) proliferation, indicating its possible involvement in cardiovascular disease. Diabetes is a major cause of cardiovascular disease. The aim of the present study was to investigate the involvement of lncRNA-SRA in type II diabetic cardiovascular disease. The plasma levels of lncRNA-SRA were identified to be significantly lower in patients with type II diabetic cardiovascular disease compared with those in type II diabetic patients without any obvious complications and in healthy controls. A 5-year follow-up study revealed that low vs. high expression levels of lncRNA-SRA were associated with an increased incidence of cardiovascular disease in type II diabetic patients. High-glucose treatment did not significantly affect the expression of lncRNA-SRA in human VSMCs in vitro. However, ectopic overexpression of lncRNA-SRA increased the viability of human VSMCs in a high-glucose environment. It was concluded that downregulation of lncRNA-SRA may participate in the development of cardiovascular disease in type II diabetic patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019